Differential expression of the neuronal CB1 cannabinoid receptor in the hippocampus of male Ts65Dn Down syndrome mouse model
Under a Creative Commons license
open access
Abbreviations
AA
arachidonic acid
ABHD12
α,β-hydrolase-12
AEA
anandamide
AD
Alzheimer-like disease
CA1, 2 or 3
Cornus Ammonis 1, 2 or 3
CB1
cannabinoid type-1 receptor
CB2
cannabinoid type-2 receptor
CD
cognitive deficit
Cnr1
CB1 encoding gene
Cnr2
CB2 encoding gene
D-FISH
double fluorescent in situ hybridization
DAGL
diacylglycerol lipase
DG
Dentate Gyrus
dHPC
dorsal hippocampus
DS
Down syndrome
eCBs
endocannabinoids
ECS
endocannabinoid system
ETA
ethanolamine
FAAH
fatty acid amide hydrolase
GAD
glutamic acid decarboxylase 65 kDa and 67 kDa
HSA21
human chromosome 21
LMol
lacunosum moleculare strata
MAGL
monoacylglycerol lipase
NAPE
N-acyl phosphatidylethanolamine
NAPE-PLD
N-acyl phosphatidylethanolamine phospholipase D
PFC
prefrontal cortex
PIP2
phosphatidylinositol 4,5-bisphosphate
PLC
phospholipase C
Po
polymorph dentate gyrus
Py
pyramidal layers
SLu
stratum lucidum
vHPC
ventral hippocampus
2-AG
2-arachidonoylglycerol
Keywords
Endocannabinoid system (ECS)
Cannabinoid type-1 receptor (CB1)
Down syndrome (DS)
Ts65Dn mouse
Hippocampus (HPC)
Cited by (0)
- 1
These authors contributed equally to this work.
- 2
Current address: Aelis Farma, 33077 Bordeaux, France.
© 2022 The Authors. Published by Elsevier Inc.